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Compact bones (CB) are major reservoirs of mouse mesenchymal stem cells (mMSC). Here, 
we established a protocol to isolate MSC from CB and tested their immunosuppressive 
potential. Collagenase type II digestion of BM-flushed CB from C57B/6 mice was performed 
to liberate mMSC precursors from bone surfaces to establish nondepleted mMSC. CB cells 
were also immunodepleted based on the expression of CD45 (leukocytes) and TER119 




 CB cells were subsequently 
used to generate depleted mMSC. CB nondepleted and depleted mMSC progenitors were 
cultured under hypoxic conditions to establish primary mMSC cultures. CB depleted mMSC 
compared to nondepleted mMSC showed greater cell numbers at sub-culturing and had 
increased functional ability to differentiate into adipocytes and osteoblasts. CB depleted 
mMSC had high purity and expressed key mMSC markers (>85% Sca-1, CD29, CD90) with 
no mature hematopoietic contaminating cells (<5% CD45, CD11b) when sub-cultured to 







cells at early passages (P1 or P2), as well as high 
percentages of contaminating CD11b
+
 (35.6%) and CD45
+
 (39.2%) cells that persisted in 
culture long-term. Depleted and nondepleted mMSC nevertheless exhibited similar potency 






 T cell proliferation, in a dendritic cell 
allostimulatory one-way mixed lymphocyte reaction. CB depleted mMSC, pre-treated with 
proinflammatory cytokines IFN-γ, TNF-α and IL-17A, CB depleted mMSC showed superior 
suppression of CD8
+
 T cell, but not CD4
+
 T cell proliferation, relative to untreated-mMSC.  
In conclusion, CB depleted mMSC established under hypoxic conditions and treated with 
selective cytokines represents a novel source of potent immunosuppressive MSC. As these 
























































































































































































cells have enhanced immune modulatory function, they may represent a superior product for 
use in clinical allotransplantation.  
Keywords: compact bone mesenchymal stem cells, immunosuppression, hypoxia, 
proinflammatory cytokines, T cells, immunodepletion 


























































































































































































The bone marrow (BM) is comprised of a heterogeneous population of stem or progenitor 
cells including the haematopoietic stem cells (HSC), endothelial progenitor cells and 
mesenchymal stem cells (MSC) [1,2]. HSC are most prevalent in the bone marrow and give 
rise to cells of myeloid and lymphoid lineages [1]. Multipotent MSC were initially described 
by Friedenstein and colleagues (1970) as a rare fraction of bone marrow cells (0.001 - 0.01%) 
in rodents that have in vitro clonogenicity potential (colony forming-unit fibroblast; CFU-F) 
with self-renewal capacity and are able to form mineralized bone tissues under osteogenic 
inductive conditions [3].  
The exact mechanisms by which human BM-derived MSC function in vivo, the route, 
dose and timing of MSC patient infusion as well as safety concerns with regards to MSC, off 
target effects, tumorgenicity [4-7] and differentiation into other cell types [8-10] remain 
unresolved. Together these issues limit the wide application of human BM MSC therapy into 
the clinic. Therefore, preclinical mouse models are widely utilized to address these issues 
associated with MSC therapy.  
Human BM-derived MSC compared to their mouse MSC (mMSC) counterparts have 
been isolated and expanded ex vivo with high purity [11]. The rarity of mMSC from the BM 
however represents a major obstacle for research aiming to dissect mechanisms of MSC 
function in vivo, optimize therapeutic strategies and address safety concerns of BM MSC 
therapy. Mouse MSC have an extremely low incidence in BM compared to human MSC, and 
require modified growth conditions and media supplements for ex vivo expansion [12,13]. 
The major challenge in BM mMSC isolation protocols is to obtain a homogenous and highly 
purified population of mMSC, with less contaminating haematopoietic cells and other non-
MSC cells or progenitor populations that co-exist in the BM niche [12-14]. Previous attempts 
























































































































































































to eliminate these contaminating cells in mMSC cultures included immunodepletion and (or) 
unique culture systems such as frequent media change, low cell density cultures, alteration to 
the standard mMSC culture media components or cell culture surfaces to promote mMSC 
adherence [15-21]. Despite these attempts, isolation of mMSC from whole BM remained 
problematic due to poor yields or purity [21-23]. Absence of standardisation in BM mMSC 
isolation protocols may be a contributing factor to the conflicting results on the in vivo 
therapeutic efficacy of mMSC in preclinical mouse models of diseases including 
allotransplantation.  
Most in vivo studies on the immunosuppressive function of MSC in preclinical murine 
models of allotransplantation use the traditionally isolated plastic-adherent selected BM 
mMSC [24-28], which contain numerous accessory cell populations. In this study, we 
established a protocol to enrich a highly purified and homogenous population of compact 
bone (CB) mMSC with potent in vitro immunosuppressive capacity that would be beneficial 
in an allotransplant setting. We employed collagenase type II digestion of BM depleted CB 
combined with immunodepletion of CD45 (lymphocyte common antigen) and TER119 
(erythroid lineages) expressing cells and hypoxia preconditioning to establish primary mMSC 




 CB progenitor cells 
with higher initial cell yields at passage 1 (P1).  Based on this isolation protocol, CB mMSC 




) T cell 
proliferation in dendritic cells (DC) allostimulatory one-way mixed lymphocyte reaction 
(MLR), that mimic an in vivo allotransplant rejection response.  

























































































































































































MATERIALS AND METHODS  
Animals 
All experimental procedures were approved by the Animal Ethics Committee of the 
University of Adelaide and conform to the guidelines established by the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes (ethics approval M-2013-
033).  
 
Mouse MSC  
Dissection of hind limbs: mMSC were isolated from BM or CB (tibia and femur) of C57BL/6 
mice (4-8 mice per mMSC isolation, 6-7 weeks old). Animals were humanely killed by 
carbon dioxide or isoflurane overdose followed by cervical dislocation. Tibia and femur were 
dissected from the hind limbs in a laminar flow hood using sterile instruments and washed 
thoroughly with cold α-MEM (50U/ml Penicillin / 50µg/ml streptomycin). Limbs were 
bisected by cutting through the knee joint. Muscle and connective tissues from bones were 
removed by scrapping the diaphysis of the bone, then pulling the tissue towards the end of the 
bone. The ends of the marrow cavity were then bisected and bones were stored in cold α-
MEM on ice until further processing.  
Harvesting BM cells from the tibia and femur: BM cells were harvested using a 21-gauge 
needle, inserted into the distal end of the femur or tibia. 5 – 10ml 5% FBS/HBSS was drawn 
through the marrow cavity and then rapidly flushed out into the tube. This process was 
repeated until the bone became completely white indicating that all marrow cells have been 
harvested. The resulting cell suspension was passed through a 70µm nylon cell strainer to 
remove bone spicules or muscle and cell clumps. The viability and yields were determined by 
























































































































































































trypan blue exclusion assay. Approximately 70x10
6
 bone marrow cells can be obtained from 
each mouse donor.  
Mouse MSC isolation from CB: CB was crushed into small pieces (1-2mm) using a sterile 
blade, allowing for subsequent enzymatic digestion to release maximum number of cells. CB 
cells were then incubated with collagenase (at varying concentrations) and DNase I (50U/ml) 
for 1-2hr at 37
o
C on a shaking platform at 240rpm. The resultant cell suspension 
(nondepleted mMSC precursors) was strained using a 70µm nylon cell strainer and bone 
chips were discarded. To isolate CB depleted mMSC, mouse CB cells were further purified 
using the EasySep
TM 
Mouse Mesenchymal Progenitor Enrichment Kit (StemCell 
Technologies; catalogue #19771) according to the manufacturer’s instructions. CB cells were 









) CB cells were seeded in tissue 
culture flasks to establish the primary CB mMSC cells lines in primary MSC media 
containing α-MEM, 20% (v/v) heat inactivated fetal bovine serum, 2mM L-glutamine 
(Multicel, USA), 1mM sodium pyruvate (Sigma Aldrich), 100μM L-ascorbate-2-phosphate, 
50U/ml penicillin and 50µg/ml streptomycin [29]. Primary CB depleted or nondepleted 
mMSC cell lines were established at 37
o
C in a hypoxic environment (5% O2, 10% CO2, 85% 
N2) in a hypoxia chamber or under normoxic conditions (21% O2), with media change 
performed every 2 days. At 70-80% confluence, adherent mMSC were detached using 0.25% 
trypsin/EDTA (Sigma) for 4min at 37
o





in tissue culture flasks and maintained in MSC media containing 
10% heat inactivated FBS. Mouse MSC growth culture conditions were optimized using 
different batches of FBS. The effect of different FBS on nondepleted mMSC progenitor cell 
enrichment as well as in mMSC morphology and growth potential following mMSC sub-
culturing were tested. The three FBS batches examined included: (1) SAFC Batch #10C126 
























































































































































































(SAFC) – previously used in mMSC isolation protocols, (2) Invitrogen Batch #1153562 
(Invitrogen) – new non-MSC qualified FBS and (3) Invitrogen Batch #981394 (Invitrogen 
MSC) –new human MSC qualified FBS. BM cell harvested from 8 mice were seeded into a 
T-75 flask and primary BM mMSC cell lines were established at 37
o
C in normoxic 
conditions.   
 
Mouse MSC characterisation  
MSC precursors form fibroblast colony-forming unit (CFU-F) when cultured in vitro [30,31]. 
For CFU-F assays, BM or depleted CB cells were plated in a 6-well plate with primary MSC 




cells/well for 5 days. Cells were 
incubated at 37
o
C in a humidified tissue culture incubator under normoxic (21% O2) or 
hypoxic conditions (5% O2). Nuclei of cells were stained with Toluidine blue stain and 
colonies were counted under an inverted light microscope (Olympus CKX41). A colony was 
defined as a cluster of ≥ 50 cells. Cobblestoned shaped colonies were excluded for CFU-F 
counts. Immunophenotype of culture expanded CB depleted and nondepleted CB mMSC 
were characterised by flow cytometry [32] (Table 1). Samples were acquired on BD 
FACSCantoII (BD Biosciences) flow cytometer and analysed on FCS express V4. CB 
mMSC were induced to differentiate into adipocytes and osteocytes as published [11]. Mouse 
MSC at passages 3 to 6 were used in experiments. 
 
Cytokine treatment of CB mMSC  
CB depleted mMSC (5x10
5 
cells) were seeded into a T-75 tissue culture flask. Cells were 
allowed to adhere overnight and replaced with fresh MSC media with either no cytokines or 
with recombinant mouse cytokines IL-17A (50ng/ml; eBioscience), IFN-γ (500U/ml, 
Peprotech) and (or) TNF-α (20ng/ml, Peprotech) [33].  

























































































































































































Dendritic cells  
DC were isolated and propagated from BALB/c mice BM precursors for 5 days in RPMI 
1640 medium supplemented with 10% FBS, β-mercaptoethanol (2µL/500ml), 1000U/ml 
recombinant mouse granulocyte macrophage colony-stimulating factor (GM-CSF; R&D 
Systems) and 500U/ml recombinant mouse IL-4 (R&D Systems) as previously described [34-
36]. On day 5, 200ng/ml lipopolysaccharide (LPS; Sigma) was added to the BM-DC culture 
for 24hr to induce DC maturation. CD11c
+
 mature DC (mDC) were positively selected using 
the EasySep
TM
 mouse CD11c positive selection kit II (StemCell Technologies; catalogue 
#18780A) according to the manufacturer’s instructions. Purified CD11c+ mDC expressed 
mDC markers (>90% CD11b, CD11c, CD40, CD80, CD83 and CD86 and MHC class II).  
 
Mouse T cells  
Splenic CD3
+
 T cells were isolated from C57BL/6 mice using the Mouse T cell Enrichment 
Column (R&D Systems; MTCC-5/10) according to the manufacturer’s instructions (>90% 
purity). Purified CD3
+
 T cells were labelled with carboxyfluorescein succinimidyl ester 
(CFSE; Invitrogen) for mouse T cell proliferation assays as per manufacturer’s instructions. T 
cells (10x10
6 
cells/ml) were stained with 0.7µl CFSE per 1ml cell suspension.  
 
Mixed lymphocyte reaction (MLR) 




 (1%) or 1x10
4
 
cells (10%) were seeded overnight into 96-well round bottom plates in a total volume of 
0.2ml complete RPMI 1640 medium. CFSE-labelled responder CD3
+
 T cells (1x10
5
cells) and 
30 Grays irradiated stimulator mDC (1x10
4
cells) at a DC to T cell ratio of 1:10. Cells were 
cultured for 3 or 5 days and T cells were harvested for analysis of CFSE-labelled T cell 
























































































































































































proliferation. Harvested CFSE-labelled T cells were also cell-surface stained with anti-CD4 




 T cells, respectively 
(Table 1).  
 
Statistics 
Statistical significances (p<0.05) were assessed by one- or two- analysis of variance 
(ANOVA) with post-Sidak multiple comparison tests or Kruskal-Wallis with post-Dunn 
multiple comparison tests. Statistical analyses were performed using the GraphPad Prism 
software (GraphPad Software, LA Jolla, CA, http://www.graphpad.com/). 


























































































































































































Optimization of compact bone mMSC isolation and culture 
We aimed to establish a protocol to enrich and isolate a highly purified and homogenous 
population of CB mMSC. Collagenase digestion is an essential step to isolate mMSC 
progenitors from CB. CB derived Sca-1
+
 cells (stem cell antigen-1) are previously known to 
be precursor cells of mMSC [37-39], providing an indication if the bone digestion step was 
sufficient to release mMSC precursors from the CB. Collagenase II (3mg/mL, 1 hr) resulted 
in high yield of CB cells and the highest of Sca-1
+
 cells (34.66%) immediately after CB 
digestion compared to all the other CB digestion conditions (Table 2). The colony forming 
efficacy of the differently digested bone fragments confirmed that the digestion protocol was 
sufficient to release mMSC precursor cells from CB, where collagenase II (3mg/mL, 1 hr) 
showed the highest CFU-F efficacy with low toxicity (>90% viability). 
FBS batches vary in quality and composition. This may affect adherence, mitotic 
expansion of primary MSC cultures as well as the retention of MSC in undifferentiated states 
[40]. All FBS batches showed no difference in the enrichment of mMSC progenitor cells 
evident by the comparable number of CFU-F in primary mMSC cultures and no aberrant 
changes in mMSC morphology (Figure 1A,B).  Invitrogen FBS was optimal for mMSC 
cultures as it favoured mMSC growth, particularly from P2 to P3 when compared to 
Invitrogen MSC FBS (Figure 1C) and was subsequently used in all mMSC isolations and 
cultures.  
Hypoxic culture conditions favoured the enrichment and growth of mMSC progenitor 
cells evident by the high numbers of CFU-F derived from these CB cells (Figure 1A, Table 
3). Precursors of mMSC were highly prevalent in the CB rather than in the bone marrow 
fraction as CB derived mMSC had higher colony forming efficiency (Figure 1A).  
























































































































































































Based on the optimization of culture conditions of CB nondepleted mMSC isolation, 
we have established a protocol to maximize the enrichment and expansion of mMSC. 
Collagenase II (1hr, 3mg/ml) digestion of the CB followed by hypoxia culture, isolated, 
selected and enhanced the clonogenicity of CB derived mMSC precursors. This protocol was 
used as a standard operating procedure for the culture and establishment of nondepleted and 
depleted mMSC cell lines from CB precursors. Depleted mMSC cell lines were established 
using these culture conditions in addition to lineage depletion of CD45 (lymphocyte common 
antigen) and TER119 cells (erythroid lineages) of the digested CB fragments with the aim to 
isolate highly pure CB mMSC precursors compared to nondepleted mMSC.  
 
CD45 and TER119 depletion of compact bone cells enhances mMSC precursor 
enrichment  
CB depleted mMSC precursors obtained following CD45 and TER119 immunodepletion 
represented only a very small fraction (0.02 – 1%) of the digested CB cells. Following 5 days 
of culture under hypoxia with media change every 2 days, there was a 5.9-fold increase in the 
numbers of CB depleted mMSC when subcultured from P0 to P1 (Figure 2C). Nondepleted 
mMSC precursors were initially seeded at a 50x higher seeding density to obtain comparative 
density and growth rates as observed with depleted mMSC at day 5 under hypoxia. There was 
however a decrease in cell numbers at P0 to P1 due to the low frequency of mMSC 
precursors in the CB nondepleted fraction (Figure 2C). There was also presence of cells with 
a cobblestoned appearance, that contaminated the nondepleted mMSC cultures, whereas 
depleted mMSC cultures showed homogeneity of cell morphology, exhibiting a fibroblastic 
MSC-like appearance as early as P0 and P1 (Figure 2B). CB depleted also showed highest 
enrichment of Sca-1
+
 cells (90.6% ± 1.141) and were homogenous in Sca-1 expression, 
























































































































































































compared to CB nondepleted mMSC (72.4% ± 3.635) at P1 (Figure 2A). The level of Sca-1 
expression was also highest in CB depleted mMSC (Figure 2A).   
Additionally, both depleted and nondepleted mMSC showed similar increase in fold 
proliferation from P1 to P4 (Figure 2C). Nondepleted mMSC however had reduced 
proliferation potential when sub-cultured to higher passages (P4 to P5; 1.5-fold) and when 
compared to depleted mMSC (3.0-fold).  
Interestingly, BM mMSC initially established under normoxia at the highest seeding 
density with frequent media change exhibited lowest Sca-1 percentages (18.0% ± 5.083) and 
expression levels (Figure 2A). BM mMSC cultures were heterogenous with cobblestone 
colonies, round adherent cells and cells were less elongated and fibroblastic-like (Figure 2B). 
Culture of BM mMSC was unsuccessful as they failed to proliferate beyond P1 and was 
therefore not used in this study.   
 
CB depleted mMSC have high purity and greater functional differentiation potential  
In subsequent experiments, we further compared and characterised the immunophenotype 
and differentiation potential of CB nondepleted and depleted mMSC. At a low passage (P2), 
depleted mMSC cultures had higher percentages of cells expressing key MSC markers Sca-1 
(94.3%), CD29 (85.0%) and CD90 (86.7%) compared to nondepleted mMSC with 71.4%, 
54.2% and 63.2% positive cells, respectively (Figure 3A). Sca-1 was also highly expressed 
by depleted mMSC relative to nondepleted mMSC at P2.  Nondepleted mMSC at a higher 





compared to P2 and were similar to depleted mMSC. Other standard positive MSC markers 
CD44 and CD105 were expressed similarly by both mMSC groups regardless of the passage.  





 (39.2%) cells expressing high levels of these markers (Figure 3B).  The 
























































































































































































percentages and the expression levels of CD11b (20.8%) and CD45 (10.3%) decreased in 





cells. Depleted mMSC also exhibited higher functional 
capacity and could differentiate more efficiently into adipocytes and osteoblasts (Figure 4A). 
The high intensity of Alizarin Red staining indicated increased number of osteocytes 
containing calcium deposit in depleted mMSC. Similarly, greater lipid formation detected by 
Oil Red O staining suggested the enhanced differentiation capacity of depleted mMSC into 
adipocytes (Figure 4A).  
 
Depleted and nondepleted mMSC exhibited comparable inhibition of T cell 
proliferation 
Nondepleted and depleted mMSC inhibited allogeneic DC stimulated T cell proliferation in a 
dose-dependent manner at days 3 and 5 of the MLR assay with similar efficacy (Figure 4B). 
Maximal immunosuppression of T cells was observed at 10% mMSC dose whereby CD4
+
 T 
cell proliferation was suppressed by up to 83.4% and 81.2% at days 3 and 5 of MLR, 
respectively, while CD8
+
 T cell proliferation was inhibited by up to 86.5% and 82.6% (Figure 
4B cumulative data; Table 4). Both nondepleted and depleted mMSC retained their 




 T cells when used at lower doses (1% 
or 0.1%).  
 
CB depleted mMSC-17 are not superior suppressors of T cells  
We have previously established that human IL-17A pre-treated MSC (MSC-17) conformed to 
untreated MSC (UT-MSC) immunophenotype and are superior suppressors of T cells [33]. 
Since CD45 and TER119 depletion of CB cells yields a highly purified and homogenous 
population of mMSC compared to nondepleted mMSC, subsequent experiments were 
























































































































































































conducted using only depleted mMSC. Here, we aimed to determine if murine CB depleted 
mMSC treated with IL-17A (mMSC-17) have similar characteristics to human MSC-17 and 
retained UT-MSC phenotype. Immunophenotype of mMSC-17 was similar to untreated 
mMSC (UT-mMSC) following 5 days of IL-17A treatment (supplementary Figure S1, A). 
UT-mMSC and mMSC-17 expressed the conventional mMSC markers Sca-1, CD29, CD44, 
CD90 and were negative for CD11b, CD31, CD34, and CD45, with no difference in 
expression levels between UT-mMSC and mMSC-17. Both UT-mMSC and mMSC-17 
retained their functional capacity and could differentiate into adipocytes and osteoblasts 
(supplementary Figure S1, B).  Additionally, mMSC-17 did not exhibit enhanced 
proliferation compared to UT-mMSC (supplementary Figure S1, C). Surprisingly, we 
identified that CB mMSC had protein expression of the IL-17 receptor IL-17RC but not IL-
17RA (supplementary Figure S1, A). Unexpectedly, when mMSC were treated with IL-17A 
for 5 days prior to use in the MLR, no enhancement of T cell immunosuppression was 
observed in the mMSC-17 groups compared to UT-mMSC (supplementary Figure S2). The 
effect of 3 days IL-17A treatment of mMSC was also investigated. However, no significant 
differences in suppression of T cell proliferation were observed between UT-mMSC and 
mMSC-17 (data not shown). 
 
TNF-α enhances the immunosuppressive effect of CB depleted mMSC 
MSC pre-treated with other inflammatory cytokines including IFN-γ and TNF-α as well as in 
a cytokine combination cocktail have previously been shown to enhance MSC 
immunosuppression [33,41,42].   Hence, we further explored the capacity of 5 day IFN-γ 
(MSC-γ), and TNF-α (MSC-TNF) treated mMSC on T cell suppression. MSC-γ showed no 
improvement in MSC inhibition of T cells, comparable to UT-MSC. Interestingly, CB 
























































































































































































depleted MSC-TNF exhibited most potent suppression on allogeneically activated CD8
+
 T 
cells at day 5 MLR by 92.6% (Figure 5).  
We also investigated if IL-17A could act synergistically with either IFN-γ (MSC-
γ/17) or TNF-α (MSC-TNF/17) or in combination of both IFN-γ and TNF-α (MSC-
γ/TNF/17) to enhance mMSC immunosuppression. Although MSC-TNF/17 augmented 
mMSC inhibition on CD8
+
 T cells relative to UT-MSC by 3.2-fold, no additional T cell 
suppression was observed with respect to mMSC treated with TNF-α alone (MSC-TNF) 
(Figure 5B). MSC-γ/17/TNF were most potent amongst all other cytokine pre-treatment at 
suppressing CD8
+
 T cell proliferation at day 3 and 5 MLR, by 2.3- and 4.2-fold, respectively 
(Figure 5A,B). MSC-γ/TNF/17 were also superior to UT-MSC at inhibiting total T cell 
proliferation at day 5 MLR (Figure 5B). The enhancement of T cell immunosuppression by 
MSC-TNF, MSC-TNF/17 and MSC-γ/TNF/17 was only evident with high mMSC doses 
(10%) (Figure 5B, supplementary Figure S3). It should be noted that TNF-α in mMSC 
cultures drastically altered MSC morphology, changing their fibroblastic-like appearance to a 
hypertrophic flattened irregular shape. TNF-α also significantly inhibited mMSC growth 
potential (data not shown).   
 


























































































































































































In this study, we have shown that compact bones (CB) have emerged to be one of the major 
reservoirs of clonogenic MSC or progenitor cells in the murine system [22,23,37,43]. The 
stem cell antigen-1 (Sca-1) has recently emerged as a potential marker to isolate mMSC 
precursors with higher clonogenicity potential, cell yields and to maintain CB mMSC in an 
undifferentiated state [37-39]. Precursors of mMSC were mostly prevalent in the CB rather 
than in the bone marrow fraction as CB derived mMSC had higher colony forming efficiency 
and percentages of highly expressing Sca-1
+
 cells, indicating greater enrichment of mMSC. 
Mouse MSC are traditionally isolated from the BM but mMSC are present at low frequencies 
where BM mMSC preparations are highly heterogeneous with many contaminating 
haematopoietic cells, monocytes, granulocytes and pre-B cell progenitors that co-adhere with 
BM mMSC cultures [12,13,21,44]. We also observed the presence of colonies with various 
morphologies including less elongated and fibroblastic-like-MSC colonies as well as cells 
with cobblestoned appearance; confirming the heterogeneity of the primary BM mMSC 
cultures.  
BM mMSC compared to CB nondepleted and depleted mMSC also exhibited low 
growth kinetics and failed to be maintained in in vitro tissue culture conditions beyond 
passage 1 (P1), despite the high seeding density to initially establish the BM mMSC cell 
lines. BM mMSC cultured under atmospheric oxygen (21% O2; normoxia) where shown to 
induce the expression of p53 and mitochondrial reactive oxygen species in mMSC [45]. 
These molecules resulted in oxidative stress, increased death and caused growth arrest of BM 
mMSC [45]. This may provide a plausible explanation to the failure to maintain BM mMSC 
propagation from whole BM beyond P1, due to long-term atmospheric oxygen exposure that 
resulted in cell growth arrest. Low oxygen tension (2% or 5% O2) has been shown to support 
























































































































































































BM mMSC clonogenicity and retained their multipotency [45-47]. However, data presented 
in this study and by other groups have shown that BM mMSC compared to their CB 
counterparts have lower clonogenicity potential and cell yields when established under 
hypoxia [39,46]. Moreover, studies using Sca-1/Ly-6A null mice suggest that Sca-1 is 
required for the regulation of mesenchymal progenitor cell self-renewal [48,49]. The very 
low percentages and levels of Sca-1
 
expressing cells detected at P1 may also be a 
confounding factor contributing to the failed self-renewal capacity of BM mMSC in our 
experiments. Hence, CB derived mMSC cell lines established under hypoxia represent an 
alternative source to BM to isolate and enrich for a highly purified population of mMSC. 
 Studies exploring the use of CB derived mMSC instead of the conventional BM 
mMSC use different methods of isolation and culture. These studies generated CB mMSC by 
the culture of the whole compact bone [23], undigested CB fragments [22], collagenase 
digestion of CB with or without FACS sorting [37,39] or by the culture of BM-flushed 
digested CB fragments [43]. All these studies employed either hypoxia or normoxic culture 
conditions to isolate mMSC from precursor cells. In the present study, we aimed to optimize, 
improvise and standardize current CB mMSC isolation and culture systems. Hence, we 
extensively compared the enrichment, growth potential, immunophenotype, functional 
differentiation capacity and the immunosuppressive properties of BM-flushed collagenase II 




 (depleted) mMSC that were established under 
hypoxia and successively passaged under normoxia. 
Although lower cell yields were obtained following CD45 and TER119 depletion of 
CB cells, there was a substantial increase in cell numbers of depleted mMSC as to CB 
nondepleted cells that were seeded at a 50x higher seeding density. This was due to the 
extremely low frequency of CB mMSC progenitors that reside in the compact bones (0.02-
1%) from whole CB digested fragments. Immunodepletion of mature hematopoietic cells 
























































































































































































CD45 (lymphocytes) and TER119 (erythroid lineages) eliminated majority of these 
contaminating cells, particularly CD45 that persist in early (P2) and long-term (P5) mMSC 
cultures as shown in this study with nondepleted mMSC. The reduced purity and high 





previously shown to persist even above P5 [23]. High frequencies of CD45
+
 cells that co-
adhere with mMSC were also evident in protocols involving the culture of whole bone 
fragments to enable mMSC to migrate out of the compact bones [22] as well as from 
collagenase digested or undigested nondepleted CB mMSC [22,39,43]. In addition, we report 
that nondepleted mMSC cultures also have high percentages of CD11b
+
 cells (monocytes, 
NK cells, granulocytes, macrophages), consistent with another report [43]. These innate 
immune CD11b
+
 cells were absent in depleted mMSC, further validating the high purity and 




 contaminants in nondepleted mMSC 
can be reduced by sub-culturing, but were not eliminated by P5. This may have compromised 
nondepleted mMSC growth capacity at later passages as well as their reduced efficacy to 
functionally differentiate into adipocytes and osteoblasts in response to classical induction 
conditions. Reduced nondepleted mMSC growth potential also represents a significant 
impediment to the generation of sufficient number of cells for in vivo infusion. In human 
studies, we and others have shown that depleting blood cells from the MSC preparations 
results in higher MSC growth rates and differentiation potential [50]consistent with our 
observed results with CB depleted mMSC.  
Greater enrichment of highly expressing Sca-1
+ 
cells (>90% positivity) were also 
evident in the depleted CB mMSC compared to nondepleted mMSC at early passages, P1 and 
P2. Early depleted mMSC cultures (P2) were also highly positive (>85%) for the expression 
of key mMSC markers CD29 and CD90. Nondepleted mMSC on the contrary exhibited a 
heterogenous population of cells that were CD29 and CD90 positive (<64%), whilst also 
























































































































































































having a negative cell fraction for these markers. These data suggest that CD45 and TER119 
immunodepletion of CB progenitors improves CB mMSC enrichment, resulting in highly 
pure and homogenous cell preparations.   
Although adipose derived mMSC (mASC) isolations can be technically easier compared 
to harvesting mMSC from the bone in a murine system, MSC-like populations from different 
sources vary in their immunophenotype, functional differentiation potential, transcriptome and 
proteome profiling [51]. Different populations of MSC are also known to respond differentially in 
an inflammatory milieu and exert different mechanisms of immune modulation [52-54]. In 
preliminary studies, we performed immunophenotypic analysis of mASC isolated from 
epididymal fat of C57B/6 mice. Early mASC cultures established under normoxia or hypoxia 
expressed lower levels and percentages of Sca-1+ cells (< 22.0%, data not shown) compared to 
CB mMSC (>90% Sca-1 positivity). Mouse ASC cultures like CB nondepleted mMSC were also 
contaminated with high percentages of hematopoietic cells CD11b (30.3%) and CD45 (33.4%) 
(data not shown), while CB depleted mMSC showed absence of these cells. From our experience 
as well as reports published by others, a large proportion of contaminating CD34+ cells (30.3%) 
persist in early mASC cultures [55,56]. Therefore, the heterogeneity of mASC cultures, similar to 
CB nondepleted mMSC may limit the overall therapeutic efficacy of mASC to control 
alloimmune responses in preclinical models of allotransplantation rejection. 
Dendritic cells (DC) are the most potent antigen presenting cells of the immune 
system. We isolated and generated LPS-matured DC from allogeneic bone marrow donors to 
be used as an antigen presenting cell to induce robust T cell proliferation. We specifically 
evaluated and compared the immunosuppressive properties of autologous nondepleted and 




 T cells). Surprisingly, we 
observed no differences in the potency of nondepleted and depleted mMSC to suppress in 
vitro allogeneic DC stimulated T cell proliferation. Nonetheless, the use of a DC stimulated T 
cell MLR is more indicative of a mechanism by which CB mMSC may modulate T cell 
























































































































































































responses, previously unidentified with CB mMSC in the literature. Previous studies 
investigating in vitro T cell immunosuppressive properties by CB mMSC have used 
nonspecific-mitogenic stimulation [43], CD3/CD28 activation of T cells [39] or allogeneic 
splenocytes (mixed population of stimulator cells) to induced T cell proliferation [43].  In this 
study, a DC-T cell MLR was used instead to more closely mimic in vivo mechanisms of cell-
mediated antigen specific immune response to the allograft [27]. Evaluating mechanisms by 
which CB mMSC modulate T cell responses in vitro in the presence of DC warrants further 
investigation.  
Despite the observed similarity of depleted and nondepleted CB mMSC to modulate T 
cell proliferation in vitro, the administration of CB nondepleted mMSC as a therapy for in 
vivo allotransplantation rejection maybe limited by several factors discovered by our study. 
Firstly, nondepleted CB mMSC tend to have an early decline in culture with reduced mMSC 
proliferative capacity and secondly, a resultant heterogenous population. The contaminating 
innate (CD11b
+
) and adaptive (CD45
+
) immune inflammatory cells may trigger undesired 
immune responses in vivo, especially if allogeneic- or third-party derived mMSC are 
administered to prevent allotransplantation rejection. These innate and adaptive inflammatory 
cells may amplify immune responses associated with graft rejection, thereby reducing the 
therapeutic efficacy of mMSC in vivo through mechanisms that we extensively reviewed in a 
previous publication [27]. For these reasons, we further explored strategies in which we can 
enhance the immunomodulatory properties of CB depleted mMSC but not nondepleted 
mMSC.  
Given that CB depleted mMSC give rise to a homogenous population with an easy 
expansion capacity, we conducted further experiments to explore strategies to enhance their 
immunomodulatory capacity. We have previously shown that proinflammatory cytokines can 
regulate MSC function to promote a superior immunomodulatory phenotype [33]. For 
























































































































































































example, IL-17A (MSC-17) or IFN-γ (MSC-γ) preconditioned human BM MSC functioned 
as superior suppressors of T cells compared to untreated MSC (UT-MSC) [33]. Interestingly, 
CB depleted mouse MSC-γ and MSC-17 differed from human MSC-γ or MSC-17 as they 
were ineffective at enhancing suppression of allogeneically stimulated T cell proliferation 
compared to UT-MSC. The combination of IL-17A in a dual cytokine cocktail with either 
IFN-γ (MSC-γ/17) or TNF-α (MSC-TNF/17) also failed to show improvements or have an 
additive effect on mMSC T cell immunosuppression. Our data is consistent with another 
study showing that the treatment of BM mMSC with IFN-γ or IL-17 alone is ineffective at 
increasing the ability of mMSC to suppress T cell proliferation in vitro [42]. Nevertheless, in 
a triple cytokine combination cocktail of IFN-γ, TNF-α and IL-17A (MSC-γ/TNF/17), CB 
depleted mMSC were shown to be superior at suppressing total T cell proliferation at day 5 
MLR, supporting findings from Han et. al. (2014). In addition to this previous study, we 
demonstrated specifically that the enhanced inhibition of CB depleted MSC-γ/TNF/17 
compared to UT-MSC was evident only on the CD8
+
 T cells but not CD4
+
 T cells at day 3 
and 5 MLR. We also report that CB MSC-TNF and MSC-TNF/17 relative to UT-MSC 
exhibited greater inhibition of only CD8
+
 T cell proliferation at day 5 MLR. Mechanistically, 
BM derived MSC-γ/TNF/17 are known to inhibit in vivo Con-A induced liver injury via the 
induction of immunosuppressive iNOS [42]. TNF-α is also known to increase MSC 
adhesiveness and migration in vitro and in vivo with improvement of cardiac function 
recovery after myocardial infarction [57]. A latter study verified that TNF-α can induce the 
expression of chemotaxis molecules including CCL2 and CCL5 by MSC [42]. TNF-α in 
combination with IFN-γ and IL-17A pre-treated BM mMSC further upregulated CCL2 and 
CCL5, while inducing the expression of other chemokines such as CXCL9 and CXCL10 in 
mMSC [42]. The functional role of immunoregulatory iNOS and chemokines in CB depleted 
























































































































































































mMSC in suppressing allogeneic DC-stimulated CD8
+ 
T cell proliferation remains to be 
elucidated.  
In summary, immunodepletion and hypoxia preconditioning of mouse CB cells 
represent a novel protocol to isolate highly purified, homogeneous and immunosuppressive 
mMSC that would be beneficial in models of allotransplantation rejection and inflammatory 




T cells, which are the key effector cells mediating mechanisms of allograft rejection. We 
have also, for the first time shown that the immunosuppressive properties of CB depleted 
mMSC on DC-stimulated T cell proliferation can be amplified by preconditioning mMSC 
with IFN-γ, TNF-α and IL-17A. A DC-T cell MLR can be a useful system to investigate the 
immunomodulatory effects of MSC on T cell via the regulation of DC. In the future, we also 
aim to compare the therapeutic efficacy of CB nondepleted and depleted mMSC to prevent 
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Figure 1. Optimization of CB mMSC isolation and culture conditions.  
(A) CB depleted of bone marrow cells from C57BL/6 mice were digested with collagenase. 
CB cells were cultured in a 6-well plate at 9x10
5
 cells/well in 3ml primary MSC media 
containing 20% FBS from: (1) previously used FBS batch, SAFC (batch #10C126). Two new 
FBS serum batches tested include: (2) normal Invitrogen FBS, Invitrogen (batch #1153562) 
and (3) Invitrogen human MSC pre-screened FBS, Invitrogen MSC (batch #981394). The 6-
well plates were cultured at either normal or under hypoxic (5% O2, 10% CO2, 85% N2) 
conditions, 37
o
C. The number of colony forming units fibroblast (CFU-F) between the 
different FBS batches were counted and compared. The figure indicates mean number of 
CFU-F per 9x10
5 
cells. (B) Morphology of mMSC examined in MSC media supplemented 
with the 3 different FBS batches. mMSC morphology was observed at the initial 
establishment of mMSC cell lines under hypoxia (Passage 0, P0) and subsequent sub-
culturing of cells from P1 to P3. Any aberrant changes in mMSC morphology were examined 
under the different FBS batches (original magnification x100). The Nikon Eclipse Ti inverted 
microscope was used to capture images. (C) C57BL/6 mice mMSC progenitors or sub-








 for P1 to P2, P2 to P3 and P3 to P4 (normoxia), respectively. At day 4 or 5 or 
confluency, mMSC were detached by trypsinization and the number of mMSC were counted. 
The figures indicate total mMSC yield cultured at P0 to P1 (under hypoxia) and P1 to P2, P2 
to P3 and P3 to P4 (under normoxia). *p<0.05 vs. normoxia culture conditions (A) or vs. 
Invitrogen (C) was determined by one-way ANOVA with post-Sidak multiple comparison 






























































































































































































Figure 2. Enrichment of mMSC progenitors by CD45 and TER119 depletion of compact 
bones.  
Bone marrow and compact bone (depleted and nondepleted) mMSC cell lines isolated from 
C57BL/6 mice were established under normoxia or hypoxia, respectively. CB nondepleted 
mMSC progenitors were obtained following collagenase digestion. CB depleted mMSC 
precursors were isolated by depleting CD45 and TER119 cells from the collagenase digested 
CB cell fraction.  (A) Sca-1 surface marker expression of mMSC at Passage 1 (P1) was 
























































































































































































assessed by flow cytometry. Histogram shows level of Sca-1 expression on mMSC and are 
depicted by the isotype control (black), depleted mMSC (blue), nondepleted mMSC (red) and 
BM mMSC (green).  Data are one representative of 3 mMSC isolations. Graphs depict % 
Sca-1 positivity and Sca-1 mean fluorescence intensity (MFI). Data are pooled from 3 mMSC 
isolations. *p<0.05 vs. depleted, **p<0.05 vs. nondepleted, ***p<0.05 vs. BM determined by 
one-way ANOVA with post-Sidak multiple comparison test. (B) Morphology of BM, 
depleted and nondepleted mMSC at Passage 0 (P0) and 1 (P1). (original magnification x100). 
The Nikon Eclipse Ti inverted microscope was used to capture images. Data are one 
representative of 4 mMSC isolations. (C) Fold increase in depleted (black bars) and 
nondepleted (grey bars) MSC numbers calculated as harvest cell number divided by the 
initial seeding density number. At confluency, mMSC were detached by trypsinization and 
the numbers of mMSC were counted. The figures indicate total mMSC yield cultured at P0 to 
P1 (under hypoxia; n=4) and P1 to P2, P2 to P3, P3 to P4 and P4 to P5 (n=3 or 4, under 
normoxia). Data are pooled from 3 (nondepleted mMSC) or 4 (depleted mMSC) independent 
experiments with 3 or 4 mMSC donors. *p<0.05 for comparison of between individual 
mMSC groups (depleted or nondepleted) upon passaging (P0 to P5), **p<0.05 for 
comparison of nondepleted mMSC (P4 to P5) vs. all other nondepleted mMSC passages. 
p<0.05 of depleted vs. nondepleted mMSC are indicated on the graph. Statistical 
significances were determined by two-way ANOVA with post-Sidak multiple comparison 
test. (A,C) Error bars depict means of ± SEM of triplicates or quadruplicates. 
 


























































































































































































Figure 3. Immunophenotype comparison of compact bone depleted and nondepleted 
mMSC.   
The expression of standard positive (A) and negative (B) MSC cell surface markers were 
assessed by flow cytometry at early (Passage 2, P2) and late (P5) cell passages in depleted 
























































































































































































and nondepleted CB mMSC. Histograms show level of surface marker expression on mMSC 
and are depicted by the isotype control (black), depleted mMSC (blue) and nondepleted 
mMSC (red). Data are one representative of 3 mMSC isolations. Graphs depict % positivity 
and mean fluorescence intensity (MFI). Data are pooled from 3 mMSC isolations. *p<0.05 
for P2 vs. P5 between individual mMSC (depleted or nondepleted) comparison groups. 
p<0.05 of depleted vs. nondepleted mMSC are indicated on the graphs. Error bars depict 
means of ± SEM of triplicates or quadruplicates. 
 


























































































































































































Figure 4. Depleted and nondepleted mMSC inhibit allogeneic T cell proliferation in a 
dose-dependent manner.  
(A) Functional differentiation of depleted and nondepleted mMSC into adipocytes (Oil red 
stained fat; original magnification x100) and osteoblasts (Alizarin red stained mineral; 
original magnification x100) for 4 weeks. The Nikon Eclipse Ti inverted microscope was 
used to capture images. Representative of 1 of 3 mMSC isolations. (B) Depleted or 
nondepleted CB mMSC were co-cultured with CFSE-labelled CD3
+
 T cells (C57BL/6 mice) 
allo-stimulated by irradiated DC (BALB/c mice) at 10% UT-MSC, 1% UT-MSC and 0.1% 
























































































































































































UT-MSC. At 3- or 5- days, T cells were isolated and cell-surface stained with anti-mouse 





 T cell proliferation was determined and represented in the graphs. MLR in the absence 
of mMSC indicates maximal T cell proliferation. Data are pooled from 9 (depleted mMSC) 
and 4 (nondepleted mMSC) independent experiments. *p<0.05 vs. MLR determined by 
Kruskal-Wallis with post-Dunn multiple comparison test. Error bars depict means of ± SEM. 
 


























































































































































































Figure 5. TNF-α enhanced mMSC suppression of T cell proliferation.  
CB depleted mMSC were either untreated (UT-MSC) or treated for 5 days with single 
recombinant cytokines: IFN-γ (MSC-γ), IL-17A (MSC-17) and TNF-α (MSC-TNF); or in a 
cytokine combination cocktail: IFN-γ and IL-17A (MSC-γ/17); TNF-α and IL-17A (MSC-
TNF/17); or IFN-γ, TNF-α and IL-17A (MSC-γ/TNF/17). Mouse MSC were co-cultured 
with CFSE-labelled CD3
+
 T cells (C57BL/6 mice) allo-stimulated by irradiated DC (BALB/c 
mice) at a 10% mMSC dose. At 3- (A) or 5- (B) days, T cells were isolated and cell-surface 
stained with anti-mouse CD4 and anti-mouse CD8 and acquired on BD FACSCanto II. 




 T cell proliferation was determined and represented in 
the graphs. MLR in the absence of mMSC indicates maximal T cell proliferation. Data are 
pooled from 6 (MLR, UT-MSC, MSC-17) and 3 (MSC-γ, MSC-TNF, MSC-γ/17, MSC-
TNF/17, MSC-γ/TNF/17) independent experiments. *p<0.05 vs. MLR determined by 
Kruskal-Wallis with post-Dunn multiple comparison test. Error bars depict means of ± SEM. 
 
 

























































































































































































Table 1 Mouse MSC antibody panel 
Antibody Clone Fluorochrome Company 
MSC phenotyping: 
Sca-1 D7 PE eBioscience 
CD29 265917 PE R&D systems 
CD90 / Thy1 778053 PE R&D systems 
CD105 MJ7/18 PE eBioscience 
CD31 390 PE eBioscience 
CD34 MEC14.7 PE Biolegend 
CD44 IM7 PE eBioscience 
CD11b M1/70 PE eBioscience 
CD45 30-F11 PE eBioscience 
IL-17RA PAJ-17R PE eBioscience 
IL-17RC Leu21-Trp465 APC R&D Systems 
    
Isotype controls     
Rat IgG2a eBR2a PE eBioscience 
Rat IgG2b eB149/10H5 PE eBioscience 
Rat IgG1 eBRG1 APC eBioscience 
Armenian Hamster IgG eBio299Arm PerCP-Cy5.5 eBioscience 
Rat IgG2a RTK2758 BV421 Biolegend 
    
T cells    
CD4 GK1.5 APC-eFluor eBioscience 
CD8 53-6.7 Pe-Cy7 eBioscience 
 









































































































































































































Collagenase I 3 1 9 2.47 59 
Collagenase II 1 1 7.95 8.69 36 
Collagenase II 1 2 5.2 11.09 78 
Collagenase II 3 1 10.3 34.66 80 
Collagenase II 3 2 13.25 2.08 55 
CB cell yield immediately after CB digestions and the % Sca-1
+
 cells were determined. Yield 
of cells was counted as the number of CB cells released immediately after CB digestion.   



























































































































































































Table 3 Mouse MSC culture condition optimization: normoxia vs. hypoxia 
 Mean CFU-F 
 Normoxia Hypoxia  
Compact bones cells 5 51 
Bone marrow cells  0 1 
 

























































































































































































Table 4. Cumulative data on CB depleted and nondepleted mMSC suppression of T cell 
proliferation  
 % proliferation ± SEM (experimental replicates) 
  Depleted Nondepleted 
T cell 
subsets 






































































































































0.1%, 1% or 10% depleted (dep) and nondepleted (nondep) UT-mMSC were co-cultured with 
CD11c
+
 mDC stimulated CD3
+




 T cell proliferation 




 T cell 
























































































































































































proliferation. Bold fonts indicate p<0.05 vs. MLR determined by Kruskal-Wallis with post-
Dunn multiple comparison test. Error bars depict means of ± SEM. 
 
























































































































































































SUPPLEMENTARY FIGURE LEGENDS 
 
 
Figure S1. Characterisation of UT-mMSC and mMSC-17. 
Compact bones derived mMSC isolated from C57BL/6 mice were either untreated (UT-
mMSC) or treated with IL-17A (MSC-17) for 5 days. (A) The expression of surface markers 
on mMSC was assessed by flow cytometry. The histograms show levels of surface marker 
expression on mMSC and are depicted by the isotype control (black), UT-MSC (green) and 
MSC-17 (blue). Data are one representative of 4 mMSC isolations. (B) Functional 
























































































































































































differentiation of mMSC into adipocytes (Oil red stained fat; original magnification x100) 
and osteoblasts (Alizarin red stained mineral; original magnification x100) for 4 weeks. The 
Nikon Eclipse Ti inverted microscope was used to capture images. Representative of 1 of 3 
mMSC isolations. (C) Fold increase in mMSC numbers calculated as harvest cell number 
divided by the initial seeding number. Cell numbers were determined by trypan blue 
exclusion assay. Data are pooled from 4 independent experiments of 4 mMSC isolations. *p< 
0.05 versus UT-MSC was determined by two-way ANOVA with post-Sidak multiple 
comparison test. Error bars depict mean ± SEM.  
 


























































































































































































Figure S2. IL-17A does not enhance mMSC suppression of T cell proliferation. 
UT-MSC or mMSC treated for 5 days with IL-17A were co-cultured with CFSE-labelled 
CD3
+
 T cells (C57BL/6 mice) allo-stimulated by irradiated DC (BALB/c mice) at 10%, 1% 
and 0.1% mMSC doses. At (A) 3- or (B) 5- days, T cells were isolated and cell-surface 
stained with anti-mouse CD4 and anti-mouse CD8 and acquired on BD FACSCanto II. 




 T cell proliferation was determined and represented in 
the graphs. MLR in the absence of mMSC indicates maximal T cell proliferation. Data are 
pooled from 3 independent experiments. *p<0.05 vs. MLR determined by two-way ANOVA 
with post-Sidak multiple comparison test. Error bars depict means of triplicates ± SEM. 
 


























































































































































































Figure S3.  TNF-α does enhance not mMSC suppression of T cell at low doses.  
CB depleted mMSC were either untreated (UT-MSC) or treated for 5 days with single 
recombinant cytokines: IFN-γ (MSC-γ), IL-17A (MSC-17) and TNF-α (MSC-TNF); or in a 
cytokine combination cocktail: IFN-γ and IL-17A (MSC-γ/17); TNF-α and IL-17A (MSC-
TNF/17); or IFN-γ, TNF-α and IL-17A (MSC-γ/TNF/17). Mouse MSC were co-cultured 
with CFSE-labelled CD3
+
 T cells (C57BL/6 mice) allo-stimulated by irradiated DC (BALB/c 
mice) at 1% (A,B) or 0.1% (C,D) mMSC doses. At 3- (A,C) or 5- (B,D) days, T cells were 
























































































































































































isolated and cell-surface stained with anti-mouse CD4 and anti-mouse CD8 and acquired on 




 T cell proliferation was determined 
and represented in the graphs. MLR in the absence of mMSC indicates maximal T cell 
proliferation. Data are pooled from 6 (MLR, UT-MSC, MSC-17) and 3 (MSC-γ, MSC-TNF, 
MSC-γ/17, MSC-TNF/17, MSC-γ/TNF/17) independent experiments. *p<0.05 vs. MLR 
determined by Kruskal-Wallis with post-Dunn multiple comparison test. Error bars depict 
means of ± SEM. 
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